LAKESHORE BIOPHARMA WTS (LSBWF) Financials
Newest figures come from the 10-K for FY2025, filed Jul 31, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LSBWF SEC filings page.
LAKESHORE BIOPHARMA WTS (LSBWF) reported $85.7M in revenue for fiscal year 2025, up 6.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business preserves high gross margins, but 2025's improvement came mainly from sharply lower operating costs rather than sales scale.
From FY2024 to FY2025, revenue was broadly stable while operating margin improved from-77.8% to-14.0% , showing a recovery too large to attribute to sales growth alone. R&D fell from$42.7M to$20.4M and SG&A also declined, so expense compression, not proven pricing power, explains most of the operating rebound.
In FY2025, the net loss of
The 1.0x current ratio leaves little short-term cushion, while low debt-to-equity means long-term borrowing is not the main financing burden. Current liabilities of
Financial Health Signals
LAKESHORE BIOPHARMA WTS does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
LAKESHORE BIOPHARMA WTS passes 5 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
LAKESHORE BIOPHARMA WTS reported a net loss of $13.9M while operations used $16.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
LAKESHORE BIOPHARMA WTS reported an operating loss of $12.0M against $2.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
LAKESHORE BIOPHARMA WTS held $15.0M in cash against $3.3M in long-term debt as of Q4 2025, with $114.9M of liabilities due within a year.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
LSBWF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q4'24 | Q4'23 |
|---|
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
LSBWF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q4'24 | Q4'23 |
|---|---|---|---|
| Total Assets | $190.5M-10.7% | $213.3M-14.8% | $250.3M |
| Current Assets | $117.3M-7.8% | $127.3M-15.6% | $150.8M |
| Cash & Equivalents | $15.0M-56.4% | $34.3M-36.3% | $53.9M |
| Inventory | $31.7M+10.6% | $28.7M+6.3% | $27.0M |
| Accounts Receivable | $69.8M+11.5% | $62.6M-7.1% | $67.4M |
| Total Liabilities | $120.9M-7.5% | $130.8M-9.3% | $144.3M |
| Current Liabilities | $114.9M+1.6% | $113.1M+17.9% | $95.9M |
| Non-Current Liabilities | $6.0M-66.0% | $17.7M-63.4% | $48.4M |
| Long-Term Debt | $3.3M-76.5% | $14.0M-67.4% | $42.8M |
| Total Equity | $69.6M-15.6% | $82.5M-22.2% | $106.0M |
| Retained Earnings | -$335.4M-3.1% | -$325.2M-19.3% | -$272.7M |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Goodwill.
LSBWF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q4'24 | Q4'23 |
|---|
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
LSBWF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q4'24 | Q4'23 |
|---|---|---|---|
| Current Ratio | 1.02-0.1x | 1.13-0.4x | 1.57 |
| Debt-to-Equity | 0.05-0.1x | 0.17-0.2x | 0.40 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Where LAKESHORE BIOPHARMA WTS Ranks
Frequently Asked Questions
What is LAKESHORE BIOPHARMA WTS's annual revenue?
LAKESHORE BIOPHARMA WTS (LSBWF) reported $85.7M in total revenue for fiscal year 2025. This represents a 6.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is LAKESHORE BIOPHARMA WTS's revenue growing?
LAKESHORE BIOPHARMA WTS (LSBWF) revenue grew by 6.0% year-over-year, from $80.8M to $85.7M in fiscal year 2025.
Is LAKESHORE BIOPHARMA WTS profitable?
No, LAKESHORE BIOPHARMA WTS (LSBWF) reported a net income of -$13.9M in fiscal year 2025, with a net profit margin of -16.3%.
What is LAKESHORE BIOPHARMA WTS's EBITDA?
LAKESHORE BIOPHARMA WTS (LSBWF) had EBITDA of -$6.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does LAKESHORE BIOPHARMA WTS have?
As of fiscal year 2025, LAKESHORE BIOPHARMA WTS (LSBWF) had $15.0M in cash and equivalents against $3.3M in long-term debt.
What is LAKESHORE BIOPHARMA WTS's gross margin?
LAKESHORE BIOPHARMA WTS (LSBWF) had a gross margin of 82.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is LAKESHORE BIOPHARMA WTS's operating margin?
LAKESHORE BIOPHARMA WTS (LSBWF) had an operating margin of -14.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is LAKESHORE BIOPHARMA WTS's net profit margin?
LAKESHORE BIOPHARMA WTS (LSBWF) had a net profit margin of -16.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is LAKESHORE BIOPHARMA WTS's return on equity (ROE)?
LAKESHORE BIOPHARMA WTS (LSBWF) has a return on equity of -20.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is LAKESHORE BIOPHARMA WTS's free cash flow?
LAKESHORE BIOPHARMA WTS (LSBWF) recorded an outflow of $18.6M in free cash flow during fiscal year 2025. This represents a 61.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is LAKESHORE BIOPHARMA WTS's operating cash flow?
LAKESHORE BIOPHARMA WTS (LSBWF) recorded an outflow of $16.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are LAKESHORE BIOPHARMA WTS's total assets?
LAKESHORE BIOPHARMA WTS (LSBWF) had $190.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are LAKESHORE BIOPHARMA WTS's capital expenditures?
LAKESHORE BIOPHARMA WTS (LSBWF) invested $1.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does LAKESHORE BIOPHARMA WTS spend on research and development?
LAKESHORE BIOPHARMA WTS (LSBWF) invested $20.4M in research and development during fiscal year 2025.
What is LAKESHORE BIOPHARMA WTS's current ratio?
LAKESHORE BIOPHARMA WTS (LSBWF) had a current ratio of 1.02 as of fiscal year 2025, which is considered adequate.
What is LAKESHORE BIOPHARMA WTS's debt-to-equity ratio?
LAKESHORE BIOPHARMA WTS (LSBWF) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is LAKESHORE BIOPHARMA WTS's return on assets (ROA)?
LAKESHORE BIOPHARMA WTS (LSBWF) had a return on assets of -7.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is LAKESHORE BIOPHARMA WTS's Piotroski F-Score?
LAKESHORE BIOPHARMA WTS (LSBWF) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are LAKESHORE BIOPHARMA WTS's earnings high quality?
LAKESHORE BIOPHARMA WTS (LSBWF) reported a net loss of $13.9M while operations used $16.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can LAKESHORE BIOPHARMA WTS cover its interest payments?
LAKESHORE BIOPHARMA WTS (LSBWF) reported an operating loss of $12.0M against $2.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.